Hims & Hers Health, Inc. (HIMS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HIMS SEC filings page.
Hims & Hers Health, Inc. (HIMS) reported $2.6B in revenue over the twelve months to Jun 30, 2026, up 28.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business reached profitability through rapid expansion, but FY2025 growth demanded far more reinvestment and balance-sheet financing than FY2024.
FY2025 operating cash flow rose to$300M from$251M , yet free cash flow fell to$57M from$198M as capital expenditures climbed to$243M from$53M . The gap shows operating profitability converted into cash, but the company retained much less after reinvestment than one year earlier.
Revenue reached
Liabilities reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Hims & Hers Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Hims & Hers Health, Inc. has an operating margin of 4.5%, meaning the company retains $5 of operating profit per $100 of revenue. This results in a moderate score of 37/100, indicating healthy but not exceptional operating efficiency. This is up from 4.2% the prior year.
Hims & Hers Health, Inc.'s revenue surged 59.0% year-over-year to $2.3B, reflecting rapid business expansion. This strong growth earns a score of 96/100.
Hims & Hers Health, Inc. has elevated debt relative to equity (D/E of 2.98), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 21/100, reflecting increased financial risk.
Hims & Hers Health, Inc.'s current ratio of 1.90 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.
While Hims & Hers Health, Inc. generated $300.0M in operating cash flow, capex of $242.6M consumed most of it, leaving $57.4M in free cash flow. This results in a low score of 51/100, reflecting heavy capital investment rather than weak cash generation.
Hims & Hers Health, Inc.'s ROE of 23.7% shows moderate profitability relative to equity, earning a score of 39/100. This is down from 26.4% the prior year.
Hims & Hers Health, Inc. scores 3.90, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.8B) relative to total liabilities ($1.6B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Hims & Hers Health, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Hims & Hers Health, Inc. generates $2.34 in operating cash flow ($300.0M OCF vs $128.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Hims & Hers Health, Inc. generated $753.2M in revenue in Q2 2026. This represents an increase of 38.2% from the same quarter a year earlier. Against the prior quarter it is up 23.9%.
Hims & Hers Health, Inc.'s EBITDA was -$67.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 282.1% from the same quarter a year earlier. Against the prior quarter it is down 20.1%.
Hims & Hers Health, Inc. reported -$86.3M in net income in Q2 2026. This represents a decrease of 303.0% from the same quarter a year earlier. Against the prior quarter it is up 6.3%.
Hims & Hers Health, Inc. earned -$0.37 per diluted share (EPS) in Q2 2026. This represents a decrease of 317.6% from the same quarter a year earlier. Against the prior quarter it is up 7.5%.
Cash & Balance Sheet
Hims & Hers Health, Inc. recorded an outflow of $68.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 228.6%.
Hims & Hers Health, Inc. held $609.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Hims & Hers Health, Inc.'s gross margin was 63.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 12.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.
Hims & Hers Health, Inc.'s operating margin was -12.9% in Q2 2026, reflecting core business profitability. This is down 17.8 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Hims & Hers Health, Inc.'s net profit margin was -11.5% in Q2 2026, showing the share of revenue converted to profit. This is down 19.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.
Hims & Hers Health, Inc.'s ROE was -26.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 34.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.0 percentage points.
Capital Allocation
Hims & Hers Health, Inc. invested $32.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 35.9% from the same quarter a year earlier. Against the prior quarter it is down 11.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
HIMS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $753.2M+38.2% | $608.1M+3.8% | $617.8M+28.4% | $599.0M+49.2% | $544.8M+72.6% | $586.0M+110.7% | $481.1M+95.1% | $401.6M+77.1% |
| Cost of Revenue | $272.4M+111.8% | $211.3M+36.1% | $173.4M+55.4% | $156.9M+87.5% | $128.6M+117.9% | $155.3M+216.5% | $111.6M+162.2% | $83.7M+112.4% |
| Gross Profit | $480.8M+15.5% | $396.8M-7.9% | $444.4M+20.3% | $442.1M+39.1% | $416.2M+62.2% | $430.7M+88.0% | $369.5M+81.1% | $317.9M+69.7% |
| SG&A Expenses | $165.4M+145.8% | $109.7M+125.6% | $76.2M+58.6% | $80.7M+80.8% | $67.3M+65.9% | $48.6M+40.6% | $48.0M+48.6% | $44.6M+24.3% |
| Operating Income | -$97.2M-463.7% | -$78.3M-235.3% | $9.2M-50.6% | $11.8M-47.2% | $26.7M+142.3% | $57.9M+484.6% | $18.6M+4749.0% | $22.4M+361.6% |
| EBITDA | -$67.7M-282.1% | -$56.4M-185.2% | $27.3M+10.6% | $29.5M+10.2% | $37.2M+153.4% | $66.2M+412.8% | $24.7M+992.0% | $26.8M+532.2% |
| Income Tax | -$6.3M+34.3% | -$9.4M-185.7% | -$2.2M+39.8% | -$3.6M+93.2% | -$9.7M-7700.0% | $11.0M+763.5% | -$3.7M-492.6% | -$52.0M-8086.9% |
| Net Income | -$86.3M-303.0% | -$92.1M-286.1% | $20.6M-20.8% | $15.8M-79.1% | $42.5M+219.7% | $49.5M+344.7% | $26.0M+1990.4% | $75.6M+1098.9% |
| EPS (Basic) | -$0.37-294.7% | -$0.40-281.8% | $0.09-18.2% | $0.07-80.0% | $0.19+216.7% | $0.22+340.0% | $0.11+1000.0% | $0.35+975.0% |
| EPS (Diluted) | -$0.37-317.6% | -$0.40-300.0% | $0.08-20.0% | $0.06-81.3% | $0.17+183.3% | $0.20+300.0% | $0.10 | $0.32+900.0% |
| Diluted Shares (Avg) | 232M-9.7% | 228M-7.4% | N/A | 249M+5.8% | 257M+9.4% | 247M+7.5% | N/A | 235M+11.9% |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
HIMS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.6B+93.3% | $2.3B+154.2% | $2.2B+204.5% | $2.2B+270.8% | $1.9B+290.8% | $891.7M+99.0% | $707.5M+60.4% | $602.3M+45.5% |
| Current Assets | $1.4B+2.1% | $1.0B+133.9% | $767.6M+93.9% | $845.3M+159.0% | $1.4B+366.0% | $447.0M+70.8% | $395.8M+49.3% | $326.4M+30.4% |
| Cash & Equivalents | $609.8M-45.8% | $222.3M-18.8% | $228.6M+3.6% | $345.8M+108.9% | $1.1B+769.8% | $273.7M+160.1% | $220.6M+128.2% | $165.5M+185.4% |
| Short-Term Investments | $231.2M+1054.3% | $528.6M+980.2% | $348.9M+337.9% | $284.0M+220.7% | $20.0M-79.6% | $48.9M-50.2% | $79.7M-35.9% | $88.6M-42.7% |
| Inventory | $87.8M-38.1% | $79.1M+3.9% | $80.1M+24.4% | $106.0M+115.8% | $141.8M+249.4% | $76.1M+155.1% | $64.4M+186.8% | $49.1M+123.3% |
| Accounts Receivable | N/A | N/A | $32.1M+426.2% | N/A | N/A | N/A | $6.1M-9.0% | N/A |
| Long-Term Investments | $0 | $0 | $351.3M | $438.3M | $0 | $0 | $0 | $0 |
| Goodwill | $1.1B+835.6% | $342.8M+191.2% | $278.3M+146.9% | $259.2M+130.0% | $117.8M+6.2% | $117.8M+6.2% | $112.7M+1.7% | $112.7M+1.7% |
| Total Liabilities | $3.3B+151.3% | $1.8B+431.7% | $1.6B+599.1% | $1.7B+918.6% | $1.3B+1009.3% | $342.4M+230.5% | $230.8M+137.6% | $162.2M+90.2% |
| Current Liabilities | $1.5B+444.8% | $618.8M+120.7% | $404.4M+82.7% | $450.8M+195.3% | $272.2M+150.5% | $280.4M+200.4% | $221.4M+150.2% | $152.6M+84.9% |
| Non-Current Liabilities | $1.8B+74.7% | $1.2B+1836.1% | $1.2B+12689.2% | $1.2B+12461.8% | $1.0B+10471.4% | $62.1M+502.8% | $9.5M+8.8% | $9.6M+246.8% |
| Total Equity | $324.1M-42.4% | $446.2M-18.8% | $540.9M+13.5% | $581.0M+32.0% | $562.7M+55.5% | $549.3M+59.4% | $476.7M+38.6% | $440.1M+33.9% |
| Retained Earnings | -$292.2M-94.6% | -$205.9M-6.9% | -$113.8M+53.0% | -$134.4M+49.9% | -$150.1M+56.3% | -$192.7M+46.0% | -$242.1M+34.2% | -$268.2M+27.4% |
Not reported in any period shown, so not listed: Long-Term Debt.
HIMS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$35.9M-88.0% | $89.4M-18.1% | $61.3M-29.0% | $148.7M+74.4% | -$19.1M-135.7% | $109.1M+322.2% | $86.4M+293.0% | $85.3M+238.5% |
| Depreciation & Amortization | $29.5M+181.7% | $22.0M+165.3% | $18.1M+198.5% | $17.7M+303.1% | $10.5M+187.3% | $8.3M+175.8% | $6.1M+128.0% | $4.4M+85.5% |
| Stock-Based Compensation | $42.1M+17.9% | $36.9M+48.3% | N/A | $40.2M+61.3% | $35.7M+48.6% | $24.9M+30.6% | N/A | $24.9M+44.1% |
| Capital Expenditures | $32.3M-35.9% | $36.3M-38.5% | $63.9M+137.5% | $69.4M+1076.3% | $50.4M+740.0% | $59.0M+321.4% | $26.9M | $5.9M |
| Free Cash Flow | -$68.2M+1.8% | $53.1M+5.9% | -$2.6M-104.4% | $79.3M-0.1% | -$69.5M-246.1% | $50.1M+323.1% | $59.5M | $79.4M |
| Investing Cash Flow | $84.5M+500.9% | -$15.4M+52.9% | -$83.7M-386.3% | -$887.4M-8421.2% | -$21.1M-371.8% | -$32.8M-351.5% | -$17.2M-183.1% | -$10.4M+66.5% |
| Financing Cash Flow | $341.8M-61.6% | -$77.9M-238.3% | -$97.5M-614.3% | -$39.0M-0.5% | $889.2M+3647.5% | -$23.0M+24.1% | -$13.7M-244.5% | -$38.8M-2390.1% |
| Share Buybacks | N/A | N/A | $80.5M+1508.0% | $9.5M-68.4% | $0-100.0% | $0-100.0% | $5.0M+150.4% | $30.0M |
Not reported in any period shown, so not listed: Dividends Paid.
HIMS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.8%-12.6pp | 65.3%-8.3pp | 71.9%-4.9pp | 73.8%-5.4pp | 76.4%-4.9pp | 73.5%-8.9pp | 76.8%-5.9pp | 79.2%-3.5pp |
| Operating Margin | -12.9%-17.8pp | -12.9%-22.8pp | 1.5%-2.4pp | 2.0%-3.6pp | 4.9%+1.4pp | 9.9%+6.3pp | 3.9%+4.0pp | 5.6%+9.3pp |
| Net Margin | -11.5%-19.3pp | -15.2%-23.6pp | 3.3%-2.1pp | 2.6%-16.2pp | 7.8%+3.6pp | 8.4%+4.4pp | 5.4%+4.9pp | 18.8%+22.2pp |
| Return on Equity | -26.6%-34.2pp | -20.6%-29.7pp | 3.8%-1.7pp | 2.7%-14.5pp | 7.5%+3.9pp | 9.0%+5.8pp | 5.5%+5.1pp | 17.2%+19.5pp |
| Return on Assets | -2.4%-4.6pp | -4.1%-9.6pp | 1.0%-2.7pp | 0.7%-11.8pp | 2.3%-0.5pp | 5.5%+3.1pp | 3.7%+3.4pp | 12.6%+14.4pp |
| Current Ratio | 0.93-4.0x | 1.69+0.1x | 1.90+0.1x | 1.88-0.3x | 4.98+2.3x | 1.59-1.2x | 1.79-1.2x | 2.14-0.9x |
| Debt-to-Equity | 10.20+7.9x | 4.08+3.5x | 2.98+2.5x | 2.84+2.5x | 2.34+2.0x | 0.62+0.3x | 0.48+0.2x | 0.37+0.1x |
| Asset Turnover | 0.21-0.1x | 0.27-0.4x | 0.29-0.4x | 0.27-0.4x | 0.29-0.4x | 0.660.0x | 0.68+0.1x | 0.67+0.1x |
| FCF Margin | -9.1%+3.7pp | 8.7%+0.2pp | -0.4%-12.8pp | 13.2%-6.5pp | -12.8%-27.8pp | 8.6%+4.3pp | 12.4% | 19.8% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Hims & Hers Health, Inc. HIMS | FY2025 | $2.3B | $128.4M | 5.5% | $6.8B | 50/100 |
| Clorox Company CLX | FY2025 | $7.1B | $810.0M | 11.4% | $9.7B | 18/100 |
| Church & Dwight Co., Inc. CHD | FY2025 | $6.2B | $736.8M | 11.9% | $22.4B | 56/100 |
| Kenvue Inc. KVUE | FY2025 | $15.1B | $1.5B | 9.7% | $33.0B | 51/100 |
| The Estee Lauder Companies Inc. EL | FY2026 | $15.0B | $182.0M | 1.2% | $33.3B | 36/100 |
| Kimberly-Clark Corp. KMB | FY2025 | $16.4B | $2.0B | 12.3% | $31.4B | 52/100 |
Where Hims & Hers Health, Inc. Ranks
Frequently Asked Questions
What is Hims & Hers Health, Inc.'s annual revenue?
Hims & Hers Health, Inc. (HIMS) reported $2.3B in total revenue for fiscal year 2025. This represents a 59.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Hims & Hers Health, Inc.'s revenue growing?
Hims & Hers Health, Inc. (HIMS) revenue grew by 59.0% year-over-year, from $1.5B to $2.3B in fiscal year 2025.
Is Hims & Hers Health, Inc. profitable?
Yes, Hims & Hers Health, Inc. (HIMS) reported a net income of $128.4M in fiscal year 2025, with a net profit margin of 5.5%.
What is Hims & Hers Health, Inc.'s EBITDA?
Hims & Hers Health, Inc. (HIMS) had EBITDA of $160.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Hims & Hers Health, Inc.'s gross margin?
Hims & Hers Health, Inc. (HIMS) had a gross margin of 73.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Hims & Hers Health, Inc.'s operating margin?
Hims & Hers Health, Inc. (HIMS) had an operating margin of 4.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Hims & Hers Health, Inc.'s net profit margin?
Hims & Hers Health, Inc. (HIMS) had a net profit margin of 5.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Hims & Hers Health, Inc.'s return on equity (ROE)?
Hims & Hers Health, Inc. (HIMS) has a return on equity of 23.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Hims & Hers Health, Inc.'s free cash flow?
Hims & Hers Health, Inc. (HIMS) generated $57.4M in free cash flow during fiscal year 2025. This represents a -71.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Hims & Hers Health, Inc.'s operating cash flow?
Hims & Hers Health, Inc. (HIMS) generated $300.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Hims & Hers Health, Inc.'s total assets?
Hims & Hers Health, Inc. (HIMS) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Hims & Hers Health, Inc.'s capital expenditures?
Hims & Hers Health, Inc. (HIMS) invested $242.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Hims & Hers Health, Inc.'s current ratio?
Hims & Hers Health, Inc. (HIMS) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.
What is Hims & Hers Health, Inc.'s debt-to-equity ratio?
Hims & Hers Health, Inc. (HIMS) had a debt-to-equity ratio of 2.98 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Hims & Hers Health, Inc.'s return on assets (ROA)?
Hims & Hers Health, Inc. (HIMS) had a return on assets of 6.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Hims & Hers Health, Inc.'s P/E ratio?
Hims & Hers Health, Inc. (HIMS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $6.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Hims & Hers Health, Inc.'s price-to-sales ratio?
Hims & Hers Health, Inc. (HIMS) trades at 2.6x sales, its market capitalization divided by revenue of $2.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $6.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Hims & Hers Health, Inc.'s Altman Z-Score?
Hims & Hers Health, Inc. (HIMS) has an Altman Z-Score of 3.90, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Hims & Hers Health, Inc.'s Piotroski F-Score?
Hims & Hers Health, Inc. (HIMS) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Hims & Hers Health, Inc.'s earnings high quality?
Hims & Hers Health, Inc. (HIMS) has an earnings quality ratio of 2.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Hims & Hers Health, Inc.?
Hims & Hers Health, Inc. (HIMS) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.